Phase 2Completed

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

An Exploratory, Open-label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Sponsor
Novartis Pharmaceuticals (Industry)
Enrollment
24 enrolled
Conditions
Lymphangioleiomyomatosis
Interventions
Everolimus
Ages
adults, older adults
Registry
NCT01059318, EUCTR2010-019825-32

Full record on ClinicalTrials.gov

From the registry

This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis

Primary outcomes

  • Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations
  • Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Registered

  5. Started